It is not currently being investigated for the treatment of psoriasis, but if the role of IL-31 in the pathogenesis of this disease becomes more established, nemolizumab could also be evaluated as a therapeutic option for the treatment of psoriasis-associated pruritus. The gene discussed is IL31; the disease is psoriasis.